Design and in Vitro Biocompatibility of a Novel Ocular Drug Delivery Device

Abstract

The capsule drug ring (CDR) is a reservoir and delivery agent, which is designed to be placed within the capsular bag during cataract surgery. Prototypes were manufactured by hot melt extrusion of Bionate II®, a polycarbonate urethane. The devices have been optimized using Avastin® as the drug of interest. In vitro biocompatibility was assessed with human lens epithelial cell (B-3), mouse macrophage (J774A.1) and mouse fibroblast (L-929) cell lines. Cell migration and proliferation were assessed after in vitro culture. Pro-inflammatory cytokines (i.e., MIP-1β, MIP-1α, MCP-1, IL-1β, TNF and TGF-β1) were quantified using cytometric bead array (CBA). Preliminary in vivo biocompatibility and pharmacokinetics testing has been performed in rabbits.

Delivery strategies for treatment of age-related ocular diseases: From a biological understanding to biomaterial solutions

“…Implants are an interesting alternative to nanoparticles for prolonged drug release. Currently under investigation, transscleral, refillable implants may provide an innovative strategy for sustained drug release [247,248].…”

Intravitreal Injectable Hydrogels for Sustained Drug Delivery in Glaucoma Treatment and Therapy

“…Intravitreal injection is one of the current methods of pharmaceutical delivery mechanisms performed as often as monthly, which can result in resistance [116]. Currently, there are alternative intraocular injections with respect to the location and drug being delivered that might be more useful [140]. These alternatives include sub-conjunctival injection and parabulbar injection, which take place underneath the conjunctiva for trans-scleral delivery [141].…”

Preclinical challenges for developing long acting intravitreal medicines

“…Iluvien  (fluocinolone acetonide in polyimide) is a slow-release and nonbioerodible intravitreal implant that releases fluocinolone acetonide at a concentration of approximately 0.2 µg/day into the vitreous up to 36 months. 58,59 Formulation strategies reported in literature to extend the duration of action of drug therapies include microparticles and microspheres, 60,61 hydrogels, [61][62][63][64][65][66][67][68][69][70][71] protein conjugation with poly(ethylene glycol) (PEG), 54,64,72,73 implants, 74,75 liposomes 76 and affinity-based drug delivery systems (e.g. targeting ocular tissues).…”